| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02604199 2014-004145-27 Details | 2019-04-16 Interventional | 2 | 58 | Entecavir Histamine Antag… Histamine H1 An… Tenofovir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… | Company decision to discontinue trial The ARC-520 Injection development program was terminated early for regulatory and business reasons secondary to findings occurring in a non-clinical toxicology study. Program termination was not due to safety findings in humans. | |||
| NCT01789047 Details | 2019-04-16 Interventional | 2 | 42 | Amantadine Topiramate Dyskinesia, Dru… Dyskinesias Parkinson Disea… Drug Induced Dy… Idiopathic Park… | Sponsor withdrew support - | |||
| NCT01739400 Details | 2019-04-16 Interventional | 3 | 217 | Macitentan Eisenmenger Com… Pulmonary Arter… | Primary endpoint of parent study AC-055-305/MAESTRO (NCT01743001) not met. The MAESTRO parent study AC-055-305 (NCT01743001) did not meet its primary endpoint. The sponsor decided to prematurely terminate this OL study on January 12th 2018. | |||
| NCT01072643 Details | 2019-04-16 Interventional | 2/3 | 4 | Dexmedetomidine Hypertension Hypertension, P… Pulmonary Hyper… | Study was terminated due to increased PVR in one subject from T0-T1 reaching the level of a
predetermined stopping rule - | |||
| NCT00562055 Details | 2019-04-16 Interventional | 2 | 0 | Atomoxetine Hyd… Reboxetine Attention Defic… Hyperkinesis Attention Defic… | This study was withdrawn due to business reasons. - | |||
| NCT00403052 Details | 2019-04-16 Interventional | 1 | 14 | 1018 oligonucle… Colorectal Neop… | Administrative reasons - | |||
| NCT00387738 Details | 2019-04-16 Interventional | 2 | 738 | Histamine Rhinitis Rhinitis, Aller… Rhinitis, Aller… | Interim data indicated that subjects exhibited no meaningful allergic disease during the first
ragweed season, making it impossible to measure treatment effect. - | |||
| NCT02577029 2015-005499-46 Details | 2019-04-12 Interventional | 2 | 79 | Entecavir Histamine Antag… Histamine H1 An… Interferon alph… Interferon-alph… Interferons Peginterferon a… Tenofovir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… Hepatitis D | Company decision to discontinue trial The ARC-520 Injection development program was terminated early for regulatory and business reasons secondary to findings occurring in a non-clinical toxicology study. Program termination was not due to safety findings in humans. | |||
| NCT02556593 Details | 2019-04-12 Interventional | 2 | 12 | Erlotinib Hydro… Brain Neoplasms Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | - - | |||
| NCT02518971 Details | 2019-04-12 Interventional | 3 | 176 | Tamsulosin Urinary Retenti… Postoperative U… | interim analysis revealed no significant difference between study groups & increased sample
size required to gain significance. - | |||
| NCT01287741 2010-024194-39 Details | 2019-04-12 Interventional | 3 | 1418 | Cyclophosphamid… Doxorubicin Obinutuzumab Prednisone Rituximab Vincristine Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Diffuse Large B… | The study was closed by the Sponsor according to the protocol-specified minimum post-treatment
follow-up period of 3 years. - | |||
| NCT02910882 Details | 2019-04-11 Interventional | 2 | 4 | Gemcitabine Adenocarcinoma Pancreatic Aden… | Safety - | |||
| NCT03553615 Details | 2019-04-10 Interventional | 2 | 0 | Ivermectin Dermatitis Dermatitis, Ato… Eczema Atopic Dermatit… | Limited clinical capacity - | |||
| NCT02706015 Details | 2019-04-10 Interventional | 3 | 0 | Caffeine Dihydroergotami… Dipyrone Headache Migraine Disord… Migraine Headac… | Strategic reasons of the company - | |||
| NCT02582996 Details | 2019-04-10 Interventional | 3 | - | Acetaminophen Caffeine Dihydroergotami… Metoclopramide Migraine Disord… Migraine | Strategic reasons of the company - | |||
| NCT01856101 2012-004123-20 Details | 2019-04-10 Interventional | 2 | 22 | Dactolisib MTOR Inhibitors Carcinoma Carcinoma, Tran… Carcinoma Trans… | Novartis decided to stop the marketing of BEZ235 - | |||
| NCT01213329 Details | 2019-04-10 Interventional | 4 | 52 | Alemtuzumab Kidney Transpla… | - Processing of blood samples was inconsistent and lab results were questionable. Research blood specimens were in addition to Standard of Care (SOC) required blood. Most research visits were planned at the same time as SOC visits. | |||
| NCT03038009 Details | 2019-04-09 Interventional | 4 | 0 | Pantoprazole Peptic Ulcer Stomach Ulcer Ulcer Gastric Ulcer I… Proton Pump Inh… Ulcer of the Ga… | A new registration has been submitted due to a redesign of the study protocol. - | |||
| NCT00923390 NCT00870389 Details | 2019-04-09 Interventional | 1 | 5 | Aldesleukin Cyclophosphamid… Fludarabine Carcinoma, Rena… Kidney Neoplasm… Kidney Cancer Renal Cancer | - - | |||
| NCT03114280 Details | 2019-04-08 Interventional | 1/2 | 0 | Carboplatin Carcinoma Carcinoma, Squa… Squamous Cell C… Head and Neck S… | MSD would not able to support the study's continuation after protocol modifications required by
ANSM through dose de-escalation of pembrolizumab - |